Zimmer Biomet Holdings (BSP:Z1BH34) Cyclically Adjusted Revenue per Share: R$56.93 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:Z1BH34 Zimmer Biomet Holdings Inc BSP:Z1BH34
62 GF Score
Price R$121.92
GF Value R$154.55
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share?

Zimmer Biomet Holdings BSP:Z1BH34 62 Cyclically Adjusted Revenue per Share is R$56.93 as of Jun. 2026. GuruFocus rates BSP:Z1BH34 with a GF Score™ of 62/100 and a GF Value™ of R$154.55 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zimmer Biomet Holdings's adjusted revenue per share for the three months ended in Jun. 2026 was R$14.465. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$56.93 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Zimmer Biomet Holdings's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zimmer Biomet Holdings was 11.30% per year. The lowest was 3.00% per year. And the median was 8.10% per year.

As of today (2026-08-06), Zimmer Biomet Holdings's current stock price is R$121.92. Zimmer Biomet Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was R$56.93. Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio of today is 2.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zimmer Biomet Holdings was 5.01. The lowest was 1.89. And the median was 3.49.


Zimmer Biomet Holdings  (BSP:Z1BH34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=121.92/56.93
=2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zimmer Biomet Holdings was 5.01. The lowest was 1.89. And the median was 3.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Related Terms


Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zimmer Biomet Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Chart

Zimmer Biomet Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.22 42.88 57.57 58.91 55.03

Zimmer Biomet Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.07 56.73 55.03 56.12 56.93

BSP:Z1BH34 vs STE, PEN, PODD: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio falls into.


BSP:Z1BH34
62GF Score
Zimmer Biomet Holdings Inc BSP:Z1BH34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zimmer Biomet Holdings's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.465/333.9520*333.9520
=14.465

Current CPI (Jun. 2026) = 333.9520.

Zimmer Biomet Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 7.347 241.428 10.163
201612 8.263 241.432 11.429
201703 7.593 243.801 10.401
201706 7.885 244.955 10.750
201709 6.960 246.819 9.417
201712 8.352 246.524 11.314
201803 8.084 249.554 10.818
201806 9.251 251.989 12.260
201809 9.185 252.439 12.151
201812 9.851 251.233 13.094
201903 9.217 254.202 12.109
201906 9.296 256.143 12.120
201909 9.415 256.759 12.246
201912 10.492 256.974 13.635
202003 10.552 258.115 13.652
202006 7.690 257.797 9.962
202009 12.492 260.280 16.028
202012 7.362 260.474 9.439
202103 10.733 264.877 13.532
202106 10.521 271.696 12.932
202109 10.562 274.310 12.858
202112 11.958 278.802 14.323
202203 9.849 287.504 11.440
202206 10.692 296.311 12.050
202209 10.409 296.808 11.712
202212 11.364 296.797 12.787
202303 11.332 301.836 12.538
202306 10.808 305.109 11.830
202309 10.310 307.789 11.186
202312 11.398 306.746 12.409
202403 11.406 312.332 12.196
202406 12.669 314.175 13.467
202409 12.441 315.301 13.177
202412 15.429 315.605 16.326
202503 13.762 319.799 14.371
202506 14.524 322.561 15.037
202509 13.498 324.800 13.878
202512 15.471 324.054 15.944
202603 13.933 330.213 14.091
202606 14.465 333.952 14.465

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$56.93 mean?
Zimmer Biomet Holdings (BSP:Z1BH34) has a Cyclically Adjusted Revenue per Share of R$56.93 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zimmer Biomet Holdings and its competitors.
Is Zimmer Biomet Holdings' Cyclically Adjusted Revenue per Share too high?
Zimmer Biomet Holdings' current Cyclically Adjusted Revenue per Share is R$56.93. Overall, Zimmer Biomet Holdings has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Cyclically Adjusted Revenue per Share compare to STE and PEN?
Zimmer Biomet Holdings' Cyclically Adjusted Revenue per Share of R$56.93 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zimmer Biomet Holdings and its competitors. Zimmer Biomet Holdings's current Cyclically Adjusted Revenue per Share is R$56.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (BSP:Z1BH34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$154.55, compared to a current price of R$121.92 — trading 21.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$56.93. Zimmer Biomet Holdings' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zimmer Biomet Holdings (BSP:Z1BH34), the current Cyclically Adjusted Revenue per Share is R$56.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (BSP:Z1BH34) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of R$121.92 is trading 21.1% below its estimated GF Value™ of R$154.55. GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.

Key valuation signals for BSP:Z1BH34:

  • Cyclically Adjusted Revenue per Share: R$56.93
  • GF Value™: R$154.55 vs. price of R$121.92 (21.1% below fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the BSP:Z1BH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
62GF Score

Get the complete analysis for BSP:Z1BH34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$121.92
Price
R$154.55
GF Value